摘要
目的观察国产替罗非班在非ST段抬高急性冠脉综合征介入治疗中的疗效和安全性。方法符合非ST段抬高急性冠脉综合征患者82例，随机分为试验组（42例）和对照组（40例），均接受经皮冠状动脉介入治疗，实验组予替罗非班负荷量10μg／kg，3min内推完后行经皮冠状动脉介入治疗，继以0．15μg／（kg·min）持续24～36h。观察30d内主要心血管事件、并发症、心功能、血小板计数。结果试验组30d内主要不良事件发生率对照组显著降低（9．5％比20．0％，P〈0．05），心电图ST段下移程度和缺血导联数明显减少（P〈0．05），围术期出血并发症较对照组略高，但差异无统计学意义。两组术后血小板计数、射血分数差异无统计学意义。结论国产替罗非班在非ST段抬高急性冠脉综合征介入治疗中可进一步减少心月几缺血事件发生率，安全有效。
Objective To investigate the efficacy and safety of tirofiban in non - ST - elevation acute coronary syndrome（NSTE ACS） patients during primary percutaneous coronary intervention （PCI）. Methods Eighty two patients with NSTE ACS who underwent primary PCI were randomly divided into two groups which were： the tirofiban ＋ PCI group （n = 42） and the primary PCI group （n = 40）. Tirofiban was predominantly initiated in the catheter laboratory before or during the intervention and maintained for 24 -36 h （ 10 μg/kg for bolus, followed by 0.15 μg/kg. 3 min infusion ）. MACE event, periprocedural complications and platelet counting were investigated at 30 days. Heart function by echo was observed. Results The incidence of the major primary end point （ refractory isehemia, new myocardial infarction and death ） at 30 days was signifi- candy lower in the tirofiban group than that in the placebo group （9.5% vs 20.0% , P 〈0.05 ）. There were also improvements in ST segment depression and the number of ischemic leads in the tirofiban group than those in the placebo group （ P 〈 0.05）. There was no major bleeding event happened. There was no statistical difference in platelet counting and EF value between the two groups. Both groups showed no thrombocytopenia. Conclusion Trofiban may further lower the incidence of isehemic event in patients with NSTE ACS on the basis of standard treatments in ACS, and is safe and effective.
出处
《中国实用医刊》
2008年第10期29-31,共3页
Chinese Journal of Practical Medicine
